Published in Biotech Law Weekly, July 21st, 2006
This patent was originally granted in Europe on August 28, 2002, but was opposed by several parties, a legal practice that is common for European patents. The amended patent claims cover certain structural requirements for siRNAs that are important for therapeutic activity.
"The outcome of the European opposition proceedings today is a positive step forward in Alnylam's strategic consolidation of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.